OncoImmunity ontvangt €2,2 miljoen om haar platform voor machinaal leren uit te rollen om de ontwikkeling van gepersonaliseerde kankerimmunotherapieën mogelijk te maken
OSLO –(BUSINESS WIRE)– Het bio-informatica bedrijf OncoImmunity heeft de prestigieuze EU SME Instrument financiering ontvangen. Het belangrijkste product van het bedrijf, de ImmuneProfiler™, is een unieke oplossing voor machinaal leren die de uitdaging van de neo-antigeenvoorspelling is aangegaan. OncoImmunity stelt hun partners in staat om de “naald in de hooiberg” uitdaging van het identificeren van de juiste cocktail van neoantigenen voor elke individuele patiënt op te lossen, en een vaccin of celtherapie te ontwerpen die uniek is afgestemd op hun specifieke tumor.
OncoImmunity Receives €2.2 Million to Roll out Its Machine-Learning Platform to Enable the Development of Personalized Cancer Immunotherapies
OSLO, Norway–(BUSINESS WIRE)– The bioinformatics company OncoImmunity has been awarded the prestigious EU SME Instrument funding. The company’s flagship product, the ImmuneProfiler™, is a unique machine learning solution that has made inroads into solving the neoantigen prediction challenge. OncoImmunity enables their partners to solve the “needle in the haystack” challenge of identifying the right cocktail of neoantigens for each individual patient, and design a vaccine or cell therapy uniquely tailored to their specific tumor.
The machine learning company is based in both Oslo Norway and Cambridge Massachusetts in the USA, and this funding will advance further its capability to tailor the ImmuneProfiler™ for specific vaccine platforms, facilitating the design of safer and more efficacious personalized cancer vaccines.
– This project matches our ambition to position OncoImmunity as the leading supplier of neoantigen identification software in the personalized cancer vaccine market, says Dr. Richard Stratford, Chief Executive Officer and Co-founder of OncoImmunity.
– The ImmuneProfiler™ is already a powerful antigen presentation prediction tool, with demonstrated utility in predicting antigens that are presented and visible to a patient’s T cells. With these funds OncoImmunity will further advance its generic platform to learn the precise constellation of potential neoantigens that are immunogenic in different vaccine delivery systems, says Dr. Trevor Clancy, Chief Scientific Officer and Co-founder of OncoImmunity.
About OncoImmunity:
OncoImmunity is a machine-learning company offering a proprietary technology to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity’s software facilitates effective patient selection for cancer immunotherapy, and identifies optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time-frame.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181217005765/en/
Contacts
Trevor Clancy Ph.D.
CSO OncoImmunity
E-mail: trevor@oncoimmunity.com
Phone: + 47 41 43 12 42